Medifast Inc. MED
Revenue decelerating Guidance initiated
The new quarter, monitored by AI. · We follow every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
Medifast develops, manufactures, and sells nutrition and weight management products, primarily under the OPTAVIA brand, through a network of independent health coaches. Coaches earn commissions on product sales and build their own client bases, making coach count and per-coach productivity the principal drivers of revenue. Revenue is generated almost entirely from product sales to coaches and their clients, with no significant subscription or institutional revenue stream disclosed separately. The company is executing a strategic repositioning toward a broader metabolic health platform, introducing the Trilivy brand ecosystem to extend beyond traditional meal replacement programs. This transformation includes new product lines, a scientific and educational institute, and internal efficiency initiatives, while the independent coach network remains the primary distribution and acquisition channel.
Advertisement
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
Medifast reported revenue of $76.4 million in 2026-Q2, a decline of 27.6% from $105.6 million in Q2 2025, as active earning coaches fell to 11,700 from 22,800 in the prior-year period 29. Revenue per active earning coach rose 41.0% to $6,529, reflecting network realignment toward more productive coaches 29. The company recorded a net loss of $3.1 million (-$0.28 per diluted share) compared to net income of $2.5 million in Q2 2025 30. Management launched the Trilivy brand and the Medifast Metabolic Health Institute as the centerpiece of a strategic repositioning toward metabolic health 30.
Management commentary on the 2026-Q2 results (8-K-EX99.1, 2026-08-03):
„In the second quarter, we continued to see signs of a turnaround in our business. Revenue remained sequentially stable, supported by steady growth in coach productivity and positive coach leadership trends. Combined with the energy and engagement demonstrated at our recent National Coach Convention, these leading indicators have historically been precursors of future growth.“ – Nick Johnson, Chief Executive Officer 30
„We're building on that progress by putting new tools in our coaches' hands, with our new brand, Trilivy, our new Reset Fuelings, and our new Medifast Metabolic Health Institute. Each of these is a meaningful step in our 3.0 strategy. Backed by our Metabolic Synchronization science and coach-led model, we believe we are on track to return to profitability in the fourth quarter and have created a foundation that supports our vision for consistent, long-term growth.“ – Nick Johnson, Chief Executive Officer 30
Revenue · 2026-Q276$m−27.7 % vs. 2025-Q2
Net profit · 2026-Q2-3$m−224.0 % vs. 2025-Q2
EPS · 2026-Q2-0.28$−227.3 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, the company guides Loss per share to 0.25 to 1.75 (initiated); Revenue to 270 million to 300 million (initiated). 30.
ProfitabilityOperating income was -$4.3 million in 2026-Q2, with gross profit margin declining 270 basis points year-over-year to 69.9%, primarily due to fixed-cost deleverage 29. SG&A expenses decreased 25.7% in absolute terms to $57.7 million but rose to 75.6% of revenue from 73.6% in Q2 2025 30. Operating cash flow was $1.7 million, capital expenditures were $1.0 million, and free cash flow was $0.7 million.
LeverageCash and equivalents totaled $71.9 million as of June 30, 2026, and combined with total investments of $97.9 million yielded $169.8 million in total liquidity with no debt outstanding 30. The company carries no financial leverage, maintaining a net cash position with no net-debt-to-EBITDA ratio applicable. The Maryland Distribution Center building and land were sold in H1 2026 for proceeds of $3.6 million, contributing to the cash balance 29.
Management viewMedifast's 3.0 strategy repositions the company from traditional weight loss toward broader metabolic health, with new brand and product infrastructure introduced in 2026-Q2 and a scientific advisory structure to support it 30. Management guided Q3 2026 revenue at $60 million to $80 million with a loss per share of $0.15 to $0.65, excluding one-time Catalyst program costs 30. Full-year 2026 revenue is guided at $270 million to $300 million with loss per share of $0.25 to $1.75, and the company expects to return to profitability in Q4 2026 30.
ChangeFor H1 2026, revenue declined 31.1% to $152.4 million from $221.3 million in H1 2025, and the net loss for the half widened to $5.2 million from net income of $1.7 million in H1 2025 29. The 48.7% year-over-year reduction in active earning coaches was the primary revenue headwind, compressing fixed-cost absorption across the business 29. H1 2026 gross profit margin contracted 370 basis points to 69.0% from 72.7% in H1 2025, driven by the same volume-related deleverage 29.
Risks (current)Client acquisition remains under sustained pressure, with rapid GLP-1 medication adoption posing a direct competitive threat to the traditional client base 29. The metabolic health and weight loss market is broadly competitive, encompassing digital tools, app-based solutions, and wearable trackers alongside traditional nutrition program providers 29. Supply chain costs, inflation, and potential changes in tariff regulations may continue to affect the cost structure and raw material availability 29.
New this reporting periodMedifast launched the Trilivy comprehensive metabolic health system and the Reset Fuelings product line in 2026-Q2, incorporating MetaVantage Technology to support metabolic health goals 30. The Medifast Metabolic Health Institute, with a dedicated Scientific Advisory Board and an educational mission, was established this quarter as part of the 3.0 strategy 30. The Catalyst program, targeting cost savings through facility rationalization and AI-related efficiencies, was also introduced in 2026-Q2 30.
Advertisement
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
OPTAVIA revenue decline and pivot to metabolic-health/GLP-1 companion nutrition
Quarterly revenue fell from $115.7m in 2025-Q1 to $75.1m in 2025-Q4 before stabilizing near $76m in 2026-Q1/Q2, while the company repositions around GLP-1 nutrition support and the new Trilivy brand (126, 29, 30)
Quarterly revenue fell from $115.7m in 2025-Q1 to $75.1m in 2025-Q4 before stabilizing near $76m in 2026-Q1/Q2, while the company repositions around GLP-1 nutrition support and the new Trilivy brand (126, 29, 30)
Core OPTAVIA revenue trajectory
Revenue declined sequentially through FY2025 (115.7 -> 105.6 -> 89.4 -> 75.1) and has held roughly flat at 76.0 then 76.4 in 2026-Q1/Q2, indicating a decelerating but stabilizing top line (126)
Revenue declined sequentially through FY2025 (115.7 -> 105.6 -> 89.4 -> 75.1) and has held roughly flat at 76.0 then 76.4 in 2026-Q1/Q2, indicating a decelerating but stabilizing top line (126)
GLP-1 companion nutrition and LifeMD collaboration
LifeMD collaboration for telehealth/GLP-1 medication access (from December 2023) plus GLP-1 Nutrition Support Plan and OPTAVIA GLP-1 kits form a recurring strategic response to GLP-1 adoption (28, 19, 16)
LifeMD collaboration for telehealth/GLP-1 medication access (from December 2023) plus GLP-1 Nutrition Support Plan and OPTAVIA GLP-1 kits form a recurring strategic response to GLP-1 adoption (28, 19, 16)
Trilivy metabolic-health brand and Reset Fueling line
Trilivy brand, Trilivy metabolic health system and Reset Fuelings launched in 2026-Q2/July 2026 alongside the Medifast Metabolic Health Institute, marking a new product family (30, 29)
Trilivy brand, Trilivy metabolic health system and Reset Fuelings launched in 2026-Q2/July 2026 alongside the Medifast Metabolic Health Institute, marking a new product family (30, 29)
Product-line renewal (OPTAVIA ASCEND, ACTIVE, Metabolic Synchronization)
OPTAVIA ASCEND mini-meal line (December 2024), OPTAVIA ACTIVE and the Metabolic Synchronization science platform (2025-Q4) extend the portfolio into next-generation ingredients (17, 25, 26)
OPTAVIA ASCEND mini-meal line (December 2024), OPTAVIA ACTIVE and the Metabolic Synchronization science platform (2025-Q4) extend the portfolio into next-generation ingredients (17, 25, 26)
Coach/field structure and compensation redesign
New compensation plan with Trilivy Coach Hub (Q3 2026), the EDGE program (2025) and Premier+ auto-ship refresh (July 2025) rework the coach-led distribution model (29, 25, 21)
New compensation plan with Trilivy Coach Hub (Q3 2026), the EDGE program (2025) and Premier+ auto-ship refresh (July 2025) rework the coach-led distribution model (29, 25, 21)
Profitability and cash
Operating income stayed negative across the last six quarters and net income swung to a -$18.1m loss in 2025-Q4; cash declined from $101.7m (2025-Q2) to $71.9m (2026-Q2) while FCF turned modestly positive at $0.7m (126)
Operating income stayed negative across the last six quarters and net income swung to a -$18.1m loss in 2025-Q4; cash declined from $101.7m (2025-Q2) to $71.9m (2026-Q2) while FCF turned modestly positive at $0.7m (126)
Sector trend: Sector demand for traditional meal-replacement weight management is softening as GLP-1 medications reshape the category, pressuring OPTAVIA volumes and margins; the company is redirecting toward medically-supported and metabolic-health offerings (GLP-1 nutrition support, Trilivy) to align with that shift (126, 29, 19).
Advertisement
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
Overview: one dot per event · click jumps to the period
2026 · 7 events
2026-Q2 · Apr – Jun 2026
„In the second quarter, we continued to see signs of a turnaround in our business. Revenue remained sequentially stable, supported by steady growth in coach productivity and positive coach leadership trends. Combined with the energy and engagement demonstrated at our recent National Coach Convention, these leading indicators have historically been precursors of future growth.“ – Nick Johnson, Chief Executive Officer 30
earnings 2026-08-03
Net loss of $3.1M ($0.28/share) versus net income of $2.5M ($0.22/share) in Q2 2025 30
Net loss of $3.1M ($0.28/share) versus net income of $2.5M ($0.22/share) in Q2 2025 30
Revenue decelerating 2026-08-03
Revenue decreased 27.6% to $76.4M in Q2 2026 as active earning coaches fell 48.7% YoY to 11,700 from 22,800 29
Revenue decreased 27.6% to $76.4M in Q2 2026 as active earning coaches fell 48.7% YoY to 11,700 from 22,800 29
Guidance initiated 2026-08-03
Full-year 2026 revenue guidance of $270M-$300M issued with loss per share of $0.25-$1.75; return to profitability expected in Q4 2026 30
Full-year 2026 revenue guidance of $270M-$300M issued with loss per share of $0.25-$1.75; return to profitability expected in Q4 2026 30
2026-Q1 · Jan – Mar 2026
„We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been leading indicators of future growth. Backed by our differentiated science, coach-led model, and a disciplined approach to managing costs, we believe we are well positioned to drive improved performance through the remainder of 2026 and a return to sustainable, long-term growth in the years ahead.“ – Dan Chard, Chief Executive Officer 28
Revenue decelerating 2026-05-04
Revenue decreased 34.3% YoY to $76.0M as active earning coaches fell 44.9% to 14,000 from 25,400 27
Revenue decreased 34.3% YoY to $76.0M as active earning coaches fell 44.9% to 14,000 from 25,400 27
Strategic pivot 2026-05-04
Company launched Metabolic Synchronization science framework (October 2025) and Premier+ auto-ship program with tiered pricing (July 2025) as part of strategic transformation beyond traditional weight loss 27
Company launched Metabolic Synchronization science framework (October 2025) and Premier+ auto-ship program with tiered pricing (July 2025) as part of strategic transformation beyond traditional weight loss 27
EBITDA turned positive 2026-05-04
EBITDA turned positive for the first time after 2 negative periods (-4.3 to +0.2 USDm). 27
EBITDA turned positive for the first time after 2 negative periods (-4.3 to +0.2 USDm). 27
2025 · 12 events
2025-Q4 · Oct – Dec 2025
„As we enter 2026, Medifast is moving from defining its business transformation strategy to executing on a new path to growth, leading to profitability as we become wholly focused on optimal metabolic health.“ – Dan Chard, Chairman and Chief Executive Officer 26
Revenue decelerating 2026-02-17
Q4 revenue declined 36.9% to $75.1M; full-year revenue fell 36.0% to $385.8M, with active earning coaches contracting 40.6% to 16,100 (26)
Q4 revenue declined 36.9% to $75.1M; full-year revenue fell 36.0% to $385.8M, with active earning coaches contracting 40.6% to 16,100 (26)
Margin compressing 2026-02-17
Gross profit margin declined 470 basis points to 69.4% in Q4 2025 from 74.1% in Q4 2024, driven by loss of leverage on fixed costs (26)
Gross profit margin declined 470 basis points to 69.4% in Q4 2025 from 74.1% in Q4 2024, driven by loss of leverage on fixed costs (26)
Guidance initiated 2026-02-17
Company reinstated annual guidance for 2026 after a two-year absence without providing guidance (26)
Company reinstated annual guidance for 2026 after a two-year absence without providing guidance (26)
2025-Q3 · Jul – Sep 2025
„With a strong balance sheet, a passionate coach community, and clinically proven plans, we believe Medifast is well positioned to become the trusted partner for millions seeking metabolic health.“ – Dan Chard, Chairman and Chief Executive Officer 24
earnings 2025-11-03
Operating loss of $4.1M in Q3 2025 compared to operating income of $2.1M in Q3 2024 (23)
Operating loss of $4.1M in Q3 2025 compared to operating income of $2.1M in Q3 2024 (23)
Revenue decelerating 2025-11-03
Revenue declined 36.2% to $89.4M from $140.2M in Q3 2024, driven by 35.0% decrease in active earning coaches to 19,500 (23)
Revenue declined 36.2% to $89.4M from $140.2M in Q3 2024, driven by 35.0% decrease in active earning coaches to 19,500 (23)
Margin compressing 2025-11-03
Gross profit margin declined 590 basis points to 69.5% from 75.4% in Q3 2024, primarily due to loss of leverage on fixed costs (23)
Gross profit margin declined 590 basis points to 69.5% from 75.4% in Q3 2024, primarily due to loss of leverage on fixed costs (23)
2025-Q2 · Apr – Jun 2025
„We are working diligently to transform our business as we look to help more people achieve optimal metabolic health. We're focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and strengthen coach success, all while maintaining a disciplined balance sheet.“ – Dan Chard, Chief Executive Officer 22
Net income turned positive 2025-08-04
Net income of $2.5M vs. net loss of $8.2M in Q2 2024; improvement included a $3.2M gain on sale of LifeMD investment and lower operating losses, not solely operational improvement (22)
Net income of $2.5M vs. net loss of $8.2M in Q2 2024; improvement included a $3.2M gain on sale of LifeMD investment and lower operating losses, not solely operational improvement (22)
Revenue decelerating 2025-08-04
Revenue declined 37.4% to $105.6M, driven by 32.7% decline in active earning OPTAVIA coaches to 22,800 (22)
Revenue declined 37.4% to $105.6M, driven by 32.7% decline in active earning OPTAVIA coaches to 22,800 (22)
Strategic pivot 2025-08-04
Launched EDGE program for progressive coach business building and Premier+ autoship refresh with tiered pricing discounts and restructured compensation (21)
Launched EDGE program for progressive coach business building and Premier+ autoship refresh with tiered pricing discounts and restructured compensation (21)
2025-Q1 · Jan – Mar 2025
„This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.“ – Dan Chard, Chief Executive Officer 20
Net income turned negative 2025-04-28
Net loss of $0.8M in Q1 2025 compared to net income of $8.3M in Q1 2024, loss per share of $0.07 (20)
Net loss of $0.8M in Q1 2025 compared to net income of $8.3M in Q1 2024, loss per share of $0.07 (20)
Revenue decelerating 2025-04-28
Revenue declined 33.8% to $115.7M from $174.7M in Q1 2024, driven by 32.8% decrease in active earning coaches to 25,400 (19)
Revenue declined 33.8% to $115.7M from $174.7M in Q1 2024, driven by 32.8% decrease in active earning coaches to 25,400 (19)
Strategic pivot 2025-04-28
Introduced GLP-1 Nutrition Support Plan with OPTAVIA ASCEND product line and established LifeMD collaboration to provide eligible customers access to GLP-1 medications where clinically appropriate (19)
Introduced GLP-1 Nutrition Support Plan with OPTAVIA ASCEND product line and established LifeMD collaboration to provide eligible customers access to GLP-1 medications where clinically appropriate (19)
2024 · 20 events
FY2024 · Jan – Dec 2024
Operating income halved 2025-02-18
Operating income more than halved YoY (126.4 to 2.9 USDm, -98%). 17
Operating income more than halved YoY (126.4 to 2.9 USDm, -98%). 17
2024-Q4 · Oct – Dec 2024
„This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications.“ – Dan Chard, Chairman & CEO 18
Revenue decelerating 2025-02-18
Q4 revenue fell 37.7% to $119.0M; active earning OPTAVIA coaches decreased 34.1% to 27,100; FY 2024 revenue declined 43.8% to $602.5M 18
Q4 revenue fell 37.7% to $119.0M; active earning OPTAVIA coaches decreased 34.1% to 27,100; FY 2024 revenue declined 43.8% to $602.5M 18
Guidance initiated 2025-02-18
Q1 2025 guidance: revenue $100-120M, diluted EPS ranging from loss of $0.50 to $0.00 per diluted share 18
Q1 2025 guidance: revenue $100-120M, diluted EPS ranging from loss of $0.50 to $0.00 per diluted share 18
Strategic pivot 2025-02-18
GLP-1 Nutrition Support Plan and Optimization Plan introduced in December 2024 alongside new OPTAVIA ASCEND product line 17
GLP-1 Nutrition Support Plan and Optimization Plan introduced in December 2024 alongside new OPTAVIA ASCEND product line 17
Operating income halved 2025-02-18
Operating income more than halved YoY (8.7 to 0.7 USDm, -92%). 126
Operating income more than halved YoY (8.7 to 0.7 USDm, -92%). 126
2024-Q3 · Jul – Sep 2024
„With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.“ – Dan Chard, Chairman & CEO 16
earnings 2024-11-04
Income from operations fell 91.7% to $2.1M from $25.5M in Q3 2023; non-GAAP adjusted income from operations fell 85.3% to $3.8M 16
Income from operations fell 91.7% to $2.1M from $25.5M in Q3 2023; non-GAAP adjusted income from operations fell 85.3% to $3.8M 16
Revenue decelerating 2024-11-04
Revenue fell 40.6% to $140.2M; active earning OPTAVIA coaches declined 36.3% to 30,000 with lower productivity per coach 15
Revenue fell 40.6% to $140.2M; active earning OPTAVIA coaches declined 36.3% to 30,000 with lower productivity per coach 15
Guidance initiated 2024-11-04
Q4 2024 guidance: revenue $100-120M, diluted loss per share $0.10 to $0.65 16
Q4 2024 guidance: revenue $100-120M, diluted loss per share $0.10 to $0.65 16
Operating income halved 2024-11-04
Operating income more than halved YoY (25.5 to 2.1 USDm, -92%). 15
Operating income more than halved YoY (25.5 to 2.1 USDm, -92%). 15
2024-Q2 · Apr – Jun 2024
„We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded target market“ – Dan Chard, Chairman & CEO 14
Net income turned negative 2024-08-05
Net loss of $8.2M ($0.75 per diluted share) versus net income of $30.3M ($2.77 per diluted share) in Q2 2023 14
Net loss of $8.2M ($0.75 per diluted share) versus net income of $30.3M ($2.77 per diluted share) in Q2 2023 14
Revenue decelerating 2024-08-05
Revenue fell 43.1% to $168.6M; active earning OPTAVIA Coaches declined 36.2% to 33,900 14
Revenue fell 43.1% to $168.6M; active earning OPTAVIA Coaches declined 36.2% to 33,900 14
Strategic pivot 2024-08-05
$25M company-led national marketing campaign launched May 2024 to drive customer acquisition via omnichannel approach 13
$25M company-led national marketing campaign launched May 2024 to drive customer acquisition via omnichannel approach 13
2024-Q1 · Jan – Mar 2024
„Fast paced medical innovation is providing greater access to medical weight loss solutions than ever before. We are transforming our OPTAVIA offer to include comprehensive support for consumers who wish to use GLP-1 medical weight loss solutions on their individual journeys to sustainable healthy lifestyles. It's a market that is estimated by a recent BCG market study to have the potential to grow to $50B or more by 2030, and it's one that we are uniquely positioned to capitalize on.“ – Dan Chard, Chairman & Chief Executive Officer 12
Revenue decelerating 2024-04-29
Revenue fell 49.9% to $174.7M; active earning OPTAVIA Coaches declined 35.6% to 37,800 with lower productivity per Coach 12
Revenue fell 49.9% to $174.7M; active earning OPTAVIA Coaches declined 35.6% to 37,800 with lower productivity per Coach 12
Margin expanding 2024-04-29
Gross profit margin expanded 220 bps to 72.8% from inventory management efficiencies and Fuel for the Future cost savings 12
Gross profit margin expanded 220 bps to 72.8% from inventory management efficiencies and Fuel for the Future cost savings 12
Strategic pivot 2024-04-29
LifeMD collaboration launched to integrate OPTAVIA coaching with GLP-1 medications and access to board-certified affiliated clinicians 12
LifeMD collaboration launched to integrate OPTAVIA coaching with GLP-1 medications and access to board-certified affiliated clinicians 12
Operating income halved 2024-04-29
Operating income more than halved YoY (53.5 to 7.9 USDm, -85%). 11
Operating income more than halved YoY (53.5 to 7.9 USDm, -85%). 11
2023 · 14 events
2023-Q4 · Oct – Dec 2023
„We are realigning our business to respond to the evolving dynamics of the weight loss industry and to aggressively execute on bold initiatives to transform our business model. We are broadening our customer acquisition activities significantly, launching a broad-based national marketing effort and leaning into the medically-supported weight loss market through our collaboration with LifeMD. This remains a challenging market, and it will take time to navigate the transformational path that we are on. However, I believe that the investments we're making in our business will broaden our addressable market and strengthen our ability to drive future growth.“ – Dan Chard, Chairman & CEO 10
Revenue decelerating 2024-02-20
Revenue decreased 43.4% to $191.0M from $337.2M in Q4 2022 as active earning OPTAVIA Coaches continued to contract 10
Revenue decreased 43.4% to $191.0M from $337.2M in Q4 2022 as active earning OPTAVIA Coaches continued to contract 10
Margin expanding 2024-02-20
Q4 gross margin rose to 74.0% from 69.3% in Q4 2022; improvement reflects Fuel for the Future cost savings and the absence of prior-year restructuring charges (base effect) 10
Q4 gross margin rose to 74.0% from 69.3% in Q4 2022; improvement reflects Fuel for the Future cost savings and the absence of prior-year restructuring charges (base effect) 10
New market 2024-02-20
Collaboration with LifeMD announced December 2023 to provide OPTAVIA customers access to board-certified clinicians and GLP-1 medications, entering the medically supported weight loss market; $10.0M equity stake purchased with commitment for additional $10.0M 9
Collaboration with LifeMD announced December 2023 to provide OPTAVIA customers access to board-certified clinicians and GLP-1 medications, entering the medically supported weight loss market; $10.0M equity stake purchased with commitment for additional $10.0M 9
Operating income halved 2024-02-20
Operating income more than halved YoY (32.6 to 8.7 USDm, -73%). 118
Operating income more than halved YoY (32.6 to 8.7 USDm, -73%). 118
2023-Q3 · Jul – Sep 2023
„We remain steadfast in our mission to help our customers create lifelong transformation and make a healthy lifestyle second nature, while maximizing stockholder value. While the actions we are now undertaking are not expected to have a meaningful impact this year, we would expect to start to see the impact of these initiatives as we move into 2024 and beyond.“ – Dan Chard, Chairman & CEO 8
Revenue decelerating 2023-11-06
Revenue decreased 39.6% to $235.9M as active earning OPTAVIA Coaches fell 28.9% to 47,100 and productivity per Coach declined 15.1% to $5,008 7
Revenue decreased 39.6% to $235.9M as active earning OPTAVIA Coaches fell 28.9% to 47,100 and productivity per Coach declined 15.1% to $5,008 7
Margin expanding 2023-11-06
Gross margin improved 270 bps to 75.2% from 72.5% due to inventory management efficiencies and lower supply chain costs from distribution center optimization 7
Gross margin improved 270 bps to 75.2% from 72.5% due to inventory management efficiencies and lower supply chain costs from distribution center optimization 7
New market 2023-11-06
OPTAVIA ACTIVE product line launched in September 2023 with premium amino acid supplements and protein powders targeting the $30 billion sports nutrition market 7
OPTAVIA ACTIVE product line launched in September 2023 with premium amino acid supplements and protein powders targeting the $30 billion sports nutrition market 7
2023-Q2 · Apr – Jun 2023
„Industry dynamics have changed numerous times over the years and Medifast has proven adept at making the necessary adjustments in its business model to thrive in new environments. Even though the operating environment remains challenging, and we continue to expect that programming adjustments, compensation dynamics, and future growth initiatives will take time to deliver meaningful results, we are confident that the changes we are making to diversify our business into new areas will have similar success.“ – Dan Chard, Chairman & Chief Executive Officer 6
Revenue decelerating 2023-08-07
Revenue decreased 34.7% to $296.2M as active earning OPTAVIA Coaches declined 21.9% to 53,100 and revenue per Coach fell 16.3% to $5,578 5
Revenue decreased 34.7% to $296.2M as active earning OPTAVIA Coaches declined 21.9% to 53,100 and revenue per Coach fell 16.3% to $5,578 5
Strategic pivot 2023-08-07
Exited Hong Kong and Singapore operations as of July 1, 2023 to prioritize resources toward higher-impact growth initiatives under the Fuel for the Future program 5
Exited Hong Kong and Singapore operations as of July 1, 2023 to prioritize resources toward higher-impact growth initiatives under the Fuel for the Future program 5
2023-Q1 · Jan – Mar 2023
„We've pleased to see revenue and operating income both ahead of expectations in the quarter, as we continue to adjust to the changing dynamics of the business environment. Sustainable long-term growth is at the core of our focus, and we are undertaking a number of initiatives to return the business to a growth trajectory. In addition to working to increase customer acquisition, we are implementing strategies that will expand our addressable market, as we target new demographic segments, geographies, and adjacent categories.“ – Dan Chard, Chairman & Chief Executive Officer 4
Revenue decelerating 2023-05-01
Revenue declined 16.4% to $349.0M as active earning OPTAVIA Coaches fell to 58,700 from 63,900 and average revenue per Coach dropped 9.0% to $5,945 3
Revenue declined 16.4% to $349.0M as active earning OPTAVIA Coaches fell to 58,700 from 63,900 and average revenue per Coach dropped 9.0% to $5,945 3
Margin compressing 2023-05-01
Gross margin declined 178 bps to 70.6% from 72.4% due to fixed-cost deleverage on lower volumes and product cost inflation 3
Gross margin declined 178 bps to 70.6% from 72.4% due to fixed-cost deleverage on lower volumes and product cost inflation 3
Advertisement
Key Figures ($m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue ($m) · annual basis, as reported
Net income ($m) · annual basis, as reported
EPS ($) · annual basis, as reported
Operating cash flow ($m) · annual basis, as reported
Revenue ($m) · quarterly basis, as reported
Net income ($m) · quarterly basis, as reported
EPS ($) · quarterly basis, as reported
Operating cash flow ($m) · quarterly basis, as reported
Cash ($m) · annual basis, as reported
Capex ($m) · annual basis, as reported
FCF ($m) · annual basis, as reported
D&A ($m) · annual basis, as reported
Cash ($m) · quarterly basis, as reported
Capex ($m) · quarterly basis, as reported
FCF ($m) · quarterly basis, as reported
D&A ($m) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2016 is on record.
Fiscal years
Amounts in $m · EPS in $ per share · as reported
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | OCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 385.8 | -14.2 | – | -18.7 | -1.70 | – | 6.9 | 25 |
| FY2024 | 602.5 | 2.9 | 0.02° | 2.1 | 0.19 | 1.84 | 24.5 | 17 |
| FY2023 | 1,072.1 | 126.4 | 134 | 99.4 | 9.10 | 9.64 | 147.7 | 9 |
Quarters
Amounts in $m · EPS in $ per share · as reported
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | EPS adj. ($) | FCF | Cash | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-03 | 76.4 | -4.3 | – | -3.1 | -0.28 | – | 0.7 | 71.9 | 29 |
| 2026-Q1* | 2026-05-04 | 76 | -3.3 | – | -2.1 | -0.19 | – | -0.8 | 71.5 | 27 |
| 2025-Q4* | 2026-02-17 | 75.1 | -7.8 | – | -18.1 | -1.65* | – | -6.6 | 89.3 | 126 |
| 2025-Q3* | 2025-11-03 | 89.4 | -4.1 | – | -2.3 | -0.21 | – | 10.8 | 99.5 | 23 |
| 2025-Q2* | 2025-08-04 | 105.6 | -1.1 | – | 2.5 | 0.22 | – | -4.8 | 101.7 | 21 |
| 2025-Q1* | 2025-04-28 | 115.7 | -1.3 | – | -0.8 | -0.07 | – | 1.9 | 91.7 | 19 |
| 2024-Q4* | 2025-02-18 | 119 | 0.7 | -2.2 | 0.8 | 0.07* | 0.10 | -7.2 | 90.9 | 17 |
| 2024-Q3* | 2024-11-04 | 140.2 | 2.1 | 3.8 | 1.1 | 0.10 | 0.35 | 7.7 | 115.3 | 15 |
| 2024-Q2* | 2024-08-05 | 168.6 | -7.9 | 12.2 | -8.2 | -0.75 | 0.92 | 11.1 | 108 | 13 |
| 2024-Q1* | 2024-04-29 | 174.7 | 7.9 | 0.01 | 8.3 | 0.76 | 0.66 | 5.4 | 97.5 | 11 |
| 2023-Q4* | 2024-02-20 | 191 | 8.7 | 16.2 | 6 | 0.55* | 1.09 | 9.6 | 94.4 | 9 |
| 2023-Q3* | 2023-11-06 | 235.9 | 25.5 | 25.5 | 23.1 | 2.12 | – | 28.3 | 112.8 | 7 |
| 2023-Q2* | 2023-08-07 | 296.2 | 38.7 | 38.7 | 30.3 | 2.77 | 2.77 | 41.4 | 147.4 | 5 |
| 2023-Q1* | 2023-05-01 | 349 | 53.5 | 0.05 | 40 | 3.67 | 3.67 | 61.9 | 123.7 | 3 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: EBITDA (adj.), Net Debt, Net Debt/EBITDA (not reported in any source for these periods).
Advertisement
Balance Sheet & Cash Flow ($m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
Amounts in $m · as reported
| Period | Published | Cash | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-17 | 89.3 | 14.2 | 6.9 | 5.6 | 1.2 | 25 |
| FY2024 | 2025-02-18 | 90.9 | 12.7 | 24.5 | 7.5 | 17 | 17 |
| FY2023 | 2024-02-20 | 94.4 | 13.1 | 147.7 | 6.5 | 141.2 | 9 |
Quarters
Amounts in $m · as reported
| Period | Published | Cash | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-03 | 71.9 | 3.4 | 1.7 | 1 | 0.7 | 29 |
| 2026-Q1 | 2026-05-04 | 71.5 | 3.5 | 0.3 | 1.1 | -0.8 | 27 |
| 2025-Q4 | 2026-02-17 | 89.3 | 3.5 | -5.3 | 1.4 | -6.6 | 126 |
| 2025-Q3 | 2025-11-03 | 99.5 | 3.5 | 12.1 | 1.4 | 10.8 | 23 |
| 2025-Q2 | 2025-08-04 | 101.7 | 4 | -3.4 | 1.4 | -4.8 | 21 |
| 2025-Q1 | 2025-04-28 | 91.7 | 3.3 | 3.4 | 1.5 | 1.9 | 19 |
| 2024-Q4 | 2025-02-18 | 90.9 | 3.2 | -4.9 | 2.3 | -7.2 | 17 |
| 2024-Q3 | 2024-11-04 | 115.3 | 3.2 | 9.1 | 1.4 | 7.7 | 15 |
| 2024-Q2 | 2024-08-05 | 108 | 3.1 | 13.1 | 1.9 | 11.1 | 13 |
| 2024-Q1 | 2024-04-29 | 97.5 | 3.3 | 7.3 | 1.8 | 5.4 | 11 |
| 2023-Q4 | 2024-02-20 | 94.4 | 3.4 | 10.5 | 0.9 | 9.6 | 9 |
| 2023-Q3 | 2023-11-06 | 112.8 | 3.4 | 29.9 | 1.7 | 28.3 | 7 |
| 2023-Q2 | 2023-08-07 | 147.4 | 3.4 | 43.1 | 1.7 | 41.4 | 5 |
| 2023-Q1 | 2023-05-01 | 123.7 | 3 | 64.1 | 2.1 | 61.9 | 3 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Advertisement
Products & M&A (15/24 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| New compensation plan and Trilivy Coach Hub platform launch | 2026-09 | Launched | 29 |
| Trilivy metabolic health system launch (2x) | 2026-06 | Launched | 29 |
| Trilivy brand launch | 2026-06 | Launched | 30 |
| Reset Fuelings launch (2x) | 2026-06 | Launched | 29 |
| Catalyst program | 2026-06 | Launched | 30 |
| Updated product line with next-generation ingredients | 2026 | Launched | 27 |
| Next-generation product line for metabolic enhancement (2x) | 2026 | Launched | 25 |
| Metabolic Synchronization (3x) | 2025-10 | Launched | 26 |
| Reward program discontinuation | 2025-07 | Launched | 25 |
| Premier+ autoship program refresh | 2025-07 | Launched | 21 |
| Premier+ auto-ship program | 2025-07 | Launched | 29 |
| Scientific advancement to further solidify OPTAVIA's role in combating metabolic dysfunction | 2025-06 | Launched | 22 |
| EDGE program | 2025-06 | Launched | 23 |
| OPTAVIA ASCEND mini meal line launch | 2025 | Launched | 25 |
| EDGE program launch emphasizing progressive business building | 2025 | Launched | 25 |
| OPTAVIA ASCEND product line with mini meals and daily nutrient pack | 2024-12 | Launched | 17 |
| GLP-1 Nutrition Support Plan and Optimization Plan | 2024-12 | Launched | 19 |
| GLP-1 Nutrition Support product kit (3×) | 2024-06 | Launched | 15 |
| OPTAVIA GLP-1 medical weight loss support offering | 2024-03 | Launched | 12 |
| National marketing campaign launch (3×) | 2024 | Launched | 15 |
| OPTAVIA Nutrition Kit for Medically Supported Weight Loss (2×) | 2023-12 | Launched | 9 |
| OPTAVIA ACTIVE EAA Blend and Whey Protein launch (2×) | 2023-09 | Launched | 17 |
| OPTAVIA ACTIVE (5×) | 2023-06 | Launched | 25 |
| GLP-1 weight loss pilot program (3×) | 2023 | Launched | 8 |
Advertisement
M&A (6)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions · 1Divestitures/exits · 5
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| LifeMD Collaboration (8×) | 2023-12 | Completed | 28 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Maryland Distribution Center sale (2×) | 2026-03 | Divested | 29 |
| Sale of LifeMD common stock investment | 2025-06 | Divested | 21 |
| LifeMD investment | 2025-06 | Divested | 23 |
| OPTAVIA convention hotel commitments exit | 2024-06 | Divested | 13 |
| Hong Kong and Singapore operations exit (2×) | 2023-06 | Divested | 7 |
Advertisement
Reported KPIs (as disclosed) (318)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-08-03 | 2026-Q2 | working capital june 30 2026 | 160.5 million | 29 |
| 2026-08-03 | 2026-Q2 | working capital december 31 2025 | 158.7 million | 29 |
| 2026-08-03 | 2026-Q2 | stockholders equity june 30 2026 | 196.4 million | 29 |
| 2026-08-03 | 2026-Q2 | stockholders equity december 31 2025 | 198.9 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash used in investing activities h1 2026 | -18.4 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash used in financing activities h1 2026 | -1.0 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash used in financing activities h1 2025 | -0.6 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash from operating activities h1 2026 | 2.0 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash from operating activities h1 2025 | less than 0.1 million | 29 |
| 2026-08-03 | 2026-Q2 | net cash from investing activities h1 2025 | 11.3 million | 29 |
| 2026-08-03 | 2026-Q2 | cash and equivalents and investment securities june 30 2026 | 169.8 million | 29 |
| 2026-08-03 | 2026-Q2 | cash and equivalents and investment securities december 31 2025 | 167.3 million | 29 |
| 2026-08-03 | 2026-Q2 | average revenue per active earning coach q2 2026 | 6,529 (USD millions) | 29 |
| 2026-08-03 | 2026-Q2 | average revenue per active earning coach q2 2025 | 4,630 (USD millions) | 29 |
| 2026-08-03 | 2026-Q2 | active earning coaches q2 2026 | 11,700 | 29 |
| 2026-08-03 | 2026-Q2 | active earning coaches q2 2025 | 22,800 | 29 |
| 2026-08-03 | 2026-Q2 | Working capital | $160.5 million | 30 |
| 2026-08-03 | 2026-Q2 | SG&A as percentage of revenue | 75.6% | 30 |
| 2026-08-03 | 2026-Q2 | Revenue per active earning coach | $6,529 | 30 |
| 2026-08-03 | 2026-Q2 | Loss from operations as percentage of revenue | 5.7% | 30 |
| 2026-08-03 | 2026-Q2 | Independent active earning coaches | 11,700 | 30 |
| 2026-08-03 | 2026-Q2 | Gross profit margin | 69.9% | 30 |
| 2026-08-03 | 2026-Q2 | Cash, Cash Equivalents, and Investment Securities | $169.8 million | 30 |
| 2026-05-04 | 2026-Q1 | Average revenue per active earning coach | $5,432 | 27 |
| 2026-05-04 | 2026-Q1 | Active earning coaches | 14,000 | 27 |
| 2026-05-04 | 2026-Q1 | Working capital | $160.4 million | 28 |
| 2026-05-04 | 2026-Q1 | SG&A as a percentage of revenue | 72.4% | 28 |
| 2026-05-04 | 2026-Q1 | Revenue per active earning coach | $5,432 | 28 |
| 2026-05-04 | 2026-Q1 | Independent active earning coaches | 14,000 | 28 |
| 2026-05-04 | 2026-Q1 | Cash, Cash Equivalents, and Investment Securities | $168.9 million | 28 |
| 2026-02-17 | FY2025 | Total lives impacted | over 3 million | 25 |
| 2026-02-17 | FY2025 | Addressable market weight loss | over $30 billion | 25 |
| 2026-02-17 | FY2025 | Active earning coaches Q4 2025 | 16,100 | 25 |
| 2026-02-17 | FY2025 | Active earning coaches Q4 2024 | 27,100 | 25 |
| 2026-02-17 | FY2025 | Active earning coaches Q3 2025 | 19,500 | 25 |
| 2026-02-17 | FY2025 | Working capital | $158.7 million | 25 |
| 2026-02-17 | FY2025 | Stockholders' equity | $198.9 million | 25 |
| 2026-02-17 | FY2025 | Selling, general, and administrative (% of revenue) | 75.0% | 25 |
| 2026-02-17 | FY2025 | Product sales (% of revenue 2025) | 96.4% | 25 |
| 2026-02-17 | FY2025 | Product sales (% of revenue 2024) | 96.8% | 25 |
| 2026-02-17 | FY2025 | Product sales (% of revenue 2023) | 97.5% | 25 |
| 2026-02-17 | FY2025 | Net cash used in investing activities (2025) | -$7.9 million | 25 |
| 2026-02-17 | FY2025 | Net cash used in investing activities (2024) | -$26.5 million | 25 |
| 2026-02-17 | FY2025 | Net cash used in financing activities (2025) | -$0.6 million | 25 |
| 2026-02-17 | FY2025 | Net cash used in financing activities (2024) | -$1.5 million | 25 |
| 2026-02-17 | FY2025 | Net cash provided by operating activities (2025) | $6.9 million | 25 |
| 2026-02-17 | FY2025 | Net cash provided by operating activities (2024) | $24.5 million | 25 |
| 2026-02-17 | FY2025 | Income (loss) from operations (% of revenue) | -3.7% | 25 |
| 2026-02-17 | FY2025 | Cash, cash equivalents and investment securities | $167.3 million | 25 |
| 2026-02-17 | FY2025 | Average revenue per active earning coach (Q4 2025) | $4,664 | 25 |
| 2026-02-17 | FY2025 | Average revenue per active earning coach (Q4 2024) | $4,391 | 25 |
| 2026-02-17 | FY2025 | Active earning coaches (Q4 2025) | 16,100 | 25 |
| 2026-02-17 | FY2025 | Active earning coaches (Q4 2024) | 27,100 | 25 |
| 2026-02-17 | 2025-Q4 | Working capital | 158.7 million | 26 |
| 2026-02-17 | 2025-Q4 | Revenue per active earning coach | $4,664 | 26 |
| 2026-02-17 | 2025-Q4 | Independent active earning coaches | 16,100 | 26 |
| 2025-11-03 | 2025-Q3 | Working capital Sep 30 2025 | $161.1 | 23 |
| 2025-11-03 | 2025-Q3 | Working capital Dec 31 2024 | $150.2 | 23 |
| 2025-11-03 | 2025-Q3 | Stockholders equity Sep 30 2025 | $214.7 | 23 |
| 2025-11-03 | 2025-Q3 | Stockholders equity Dec 31 2024 | $210.1 | 23 |
| 2025-11-03 | 2025-Q3 | R&D costs 9M 2025 | $3.3 | 23 |
| 2025-11-03 | 2025-Q3 | R&D costs 9M 2024 | $3.3 | 23 |
| 2025-11-03 | 2025-Q3 | R&D costs Q3 2025 | $1.1 | 23 |
| 2025-11-03 | 2025-Q3 | R&D costs Q3 2024 | $1.1 | 23 |
| 2025-11-03 | 2025-Q3 | Product sales % of revenue 9M 2025 | 96% | 23 |
| 2025-11-03 | 2025-Q3 | Product sales % of revenue 9M 2024 | 97% | 23 |
| 2025-11-03 | 2025-Q3 | Product sales % of revenue Q3 2025 | 96% | 23 |
| 2025-11-03 | 2025-Q3 | Product sales % of revenue Q3 2024 | 97% | 23 |
| 2025-11-03 | 2025-Q3 | Net cash used in investing activities 9M 2025 | $3.0 | 23 |
| 2025-11-03 | 2025-Q3 | Net cash used in investing activities 9M 2024 | $7.1 | 23 |
| 2025-11-03 | 2025-Q3 | Net cash used in financing activities 9M 2025 | $0.6 | 23 |
| 2025-11-03 | 2025-Q3 | Net cash used in financing activities 9M 2024 | $1.5 | 23 |
| 2025-11-03 | 2025-Q3 | Net cash provided by operating activities 9M 2025 | $12.1 | 23 |
| 2025-11-03 | 2025-Q3 | Net cash provided by operating activities 9M 2024 | $29.4 | 23 |
| 2025-11-03 | 2025-Q3 | Diluted loss per share 9M 2025 | $(0.05) | 23 |
| 2025-11-03 | 2025-Q3 | Diluted loss per share Q3 2025 | $(0.21) | 23 |
| 2025-11-03 | 2025-Q3 | Diluted EPS 9M 2024 | $0.12 | 23 |
| 2025-11-03 | 2025-Q3 | Diluted EPS Q3 2024 | $0.10 | 23 |
| 2025-11-03 | 2025-Q3 | Clients impacted | more than 3 million | 23 |
| 2025-11-03 | 2025-Q3 | Cash, equivalents and investment securities Sep 30 2025 | $173.5 | 23 |
| 2025-11-03 | 2025-Q3 | Cash, equivalents and investment securities Dec 31 2024 | $162.3 | 23 |
| 2025-11-03 | 2025-Q3 | Avg. revenue per active earning OPTAVIA coach Q3 2025 | $4,585 | 23 |
| 2025-11-03 | 2025-Q3 | Avg. revenue per active earning OPTAVIA coach Q3 2024 | $4,672 | 23 |
| 2025-11-03 | 2025-Q3 | Active earning OPTAVIA coaches Sep 30 2025 | 19,500 | 23 |
| 2025-11-03 | 2025-Q3 | Active earning OPTAVIA coaches Sep 30 2024 | 30,000 | 23 |
| 2025-11-03 | 2025-Q3 | Revenue per active earning coach | 4,585 (USD millions) | 24 |
| 2025-11-03 | 2025-Q3 | Cash, equivalents and investment securities | 173.5 million | 24 |
| 2025-11-03 | 2025-Q3 | Active Coaches | 19,500 | 24 |
| 2025-08-04 | 2025-Q2 | Revenue per active earning OPTAVIA coach Q2 | $4,630 | 21 |
| 2025-08-04 | 2025-Q2 | lives impacted | more than 3 million | 21 |
| 2025-08-04 | 2025-Q2 | active earning OPTAVIA coaches | 22,800 | 21 |
| 2025-08-04 | 2025-Q2 | SG&A as percentage of revenue | 73.6% | 22 |
| 2025-08-04 | 2025-Q2 | Revenue per active earning coach | $4,630 | 22 |
| 2025-08-04 | 2025-Q2 | Loss from operations as percentage of revenue | 1.0% | 22 |
| 2025-08-04 | 2025-Q2 | loss from operations | $1.1 million | 22 |
| 2025-08-04 | 2025-Q2 | Gross profit margin | 72.6% | 22 |
| 2025-08-04 | 2025-Q2 | Cash, equivalents and investment securities | $162.7 million | 22 |
| 2025-08-04 | 2025-Q2 | Active Coaches | 22,800 | 22 |
| 2025-04-28 | 2025-Q1 | working capital | $152.9 million | 19 |
| 2025-04-28 | 2025-Q1 | stockholders' equity | $211.0 million | 19 |
| 2025-04-28 | 2025-Q1 | net cash used in investing activities | $2.1 million | 19 |
| 2025-04-28 | 2025-Q1 | net cash used in financing activities | $0.6 million | 19 |
| 2025-04-28 | 2025-Q1 | net cash provided by operating activities | $3.4 million | 19 |
| 2025-04-28 | 2025-Q1 | cash, cash equivalents and investments | $164.6 million | 19 |
| 2025-04-28 | 2025-Q1 | average revenue per active earning OPTAVIA coach | $4,556 | 19 |
| 2025-04-28 | 2025-Q1 | active earning OPTAVIA coaches | 25,400 | 19 |
| 2025-04-28 | 2025-Q1 | Revenue per active earning coach | $4,556 | 20 |
| 2025-04-28 | 2025-Q1 | independent active earning OPTAVIA coaches | 25,400 | 20 |
| 2025-04-28 | 2025-Q1 | Cash, Cash Equivalents, and Investment Securities | $164.6 million | 20 |
| 2025-02-18 | FY2024 | weight regain after GLP-1 discontinuation | two-thirds | 17 |
| 2025-02-18 | FY2024 | weight loss with fewer coaching calls | 6.7 lbs. | 17 |
| 2025-02-18 | FY2024 | weight loss with 75% coaching calls | 15.2 lbs. | 17 |
| 2025-02-18 | FY2024 | US population wanting weight loss | roughly 75% | 17 |
| 2025-02-18 | FY2024 | US adults overweight or obese | nearly three-quarters | 17 |
| 2025-02-18 | FY2024 | US adults obese Aug 2021 - Aug 2023 | more than 40% | 17 |
| 2025-02-18 | FY2024 | total potential customer pool | about 200 million | 17 |
| 2025-02-18 | FY2024 | scientific journal publications | 36 | 17 |
| 2025-02-18 | FY2024 | people recognizing lifestyle changes needed | 96% | 17 |
| 2025-02-18 | FY2024 | people confident managing alone | only 17% | 17 |
| 2025-02-18 | FY2024 | peer reviewed scientific publications | over 73 | 17 |
| 2025-02-18 | FY2024 | overweight obese population finding meal plans effective | approximately 70% | 17 |
| 2025-02-18 | FY2024 | OPTAVIA fueling variety | more than 45 | 17 |
| 2025-02-18 | FY2024 | manufacturing unit sales percentage | approximately 40% | 17 |
| 2025-02-18 | FY2024 | LIVEWELL engagement | over 85% | 17 |
| 2025-02-18 | FY2024 | GLP-1 market size 2030 | $50 billion or more | 17 |
| 2025-02-18 | FY2024 | GLP-1 discontinuation after 6 months | about one-third | 17 |
| 2025-02-18 | FY2024 | GLP-1 discontinuation after 12 months | half or more | 17 |
| 2025-02-18 | FY2024 | customers impacted | more than 3 million | 17 |
| 2025-02-18 | FY2024 | completed research studies | 28 | 17 |
| 2025-02-18 | FY2024 | company led marketing expenses 2024 | $22.9 million | 17 |
| 2025-02-18 | FY2024 | coaches who were customers first | about 90% | 17 |
| 2025-02-18 | FY2024 | coach leaders completed GLP-1 training | more than 95% | 17 |
| 2025-02-18 | FY2024 | co manufactured unit sales percentage | 60% | 17 |
| 2025-02-18 | FY2024 | average quarterly revenue per active earning OPTAVIA coach | $4,391 | 17 |
| 2025-02-18 | FY2024 | AICED program monthly usage | 65% | 17 |
| 2025-02-18 | FY2024 | AICED program activation rate | 93% | 17 |
| 2025-02-18 | FY2024 | Addressable market weight loss | over $30 billion | 17 |
| 2025-02-18 | FY2024 | active earning OPTAVIA coaches | 27,100 | 17 |
| 2025-02-18 | FY2024 | Active earning coaches | 27,100 | 17 |
| 2025-02-18 | FY2024 | active coaches supporting GLP-1 clients | over 40% | 17 |
| 2025-02-18 | FY2024 | Active Coaches Q3 2024 | 30,000 | 17 |
| 2025-02-18 | FY2024 | Active Coaches Dec 31 2023 | 41,100 | 17 |
| 2025-02-18 | 2024-Q4 | Revenue per active earning coach | $4,391 | 18 |
| 2025-02-18 | 2024-Q4 | independent active earning OPTAVIA coaches | 27,100 | 18 |
| 2025-02-18 | 2024-Q4 | Cash, Cash Equivalents, and Investment Securities | $162.3 million | 18 |
| 2024-11-04 | 2024-Q3 | working capital | $152.6 million | 15 |
| 2024-11-04 | 2024-Q3 | stockholders' equity | $207.3 million | 15 |
| 2024-11-04 | 2024-Q3 | Cash, Cash Equivalents and Investment Securities | $170.0 million | 15 |
| 2024-11-04 | 2024-Q3 | Average Revenue per Active Earning OPTAVIA Coach (Three Months) | $4,672 | 15 |
| 2024-11-04 | 2024-Q3 | Average Revenue per Active Earning OPTAVIA Coach (Nine Months) | $4,754 | 15 |
| 2024-11-04 | 2024-Q3 | active earning OPTAVIA coaches | 30,000 | 15 |
| 2024-11-04 | 2024-Q3 | SG&A as percentage of revenue | 73.9% | 16 |
| 2024-11-04 | 2024-Q3 | Revenue per active earning coach | $4,672 | 16 |
| 2024-11-04 | 2024-Q3 | Non-GAAP Adjusted Income from Operations as % of Revenue | 2.7% | 16 |
| 2024-11-04 | 2024-Q3 | independent active earning OPTAVIA coaches | 30,000 | 16 |
| 2024-11-04 | 2024-Q3 | Income from Operations as % of Revenue | 1.5% | 16 |
| 2024-11-04 | 2024-Q3 | Gross profit margin | 75.4% | 16 |
| 2024-11-04 | 2024-Q3 | Cash, Cash Equivalents, and Investment Securities | $170.0 million | 16 |
| 2024-08-05 | 2024-Q2 | Average Revenue per Active Earning Coach (Three Months) | 4,972 (USD thousands) | 13 |
| 2024-08-05 | 2024-Q2 | Average Revenue per Active Earning Coach (Six Months) | 4,788 (USD thousands) | 13 |
| 2024-08-05 | 2024-Q2 | Active earning coaches | 33,900 | 13 |
| 2024-08-05 | 2024-Q2 | SG&A as a percentage of revenue | 77.9% | 14 |
| 2024-08-05 | 2024-Q2 | Revenue per Active Earning Coach | $4,972 | 14 |
| 2024-08-05 | 2024-Q2 | Non-GAAP Adjusted Gross Profit Margin | 74.8% | 14 |
| 2024-08-05 | 2024-Q2 | Non-GAAP Adjusted SG&A as % of Revenue | 67.5% | 14 |
| 2024-08-05 | 2024-Q2 | Independent Active Earning OPTAVIA Coaches | 33,900 | 14 |
| 2024-08-05 | 2024-Q2 | Gross profit margin | 73.2% | 14 |
| 2024-08-05 | 2024-Q2 | Debt | zero | 14 |
| 2024-08-05 | 2024-Q2 | Cash, Cash Equivalents, and Investment Securities | $163.5 million | 14 |
| 2024-04-29 | 2024-Q1 | Working Capital (March 31, 2024) | 142.4 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Working Capital (December 31, 2023) | 131.7 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Uncommitted Incremental Facility | 100.0 | 11 |
| 2024-04-29 | 2024-Q1 | Stockholders' Equity (March 31, 2024) | 211.0 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Stockholders' Equity (December 31, 2023) | 201.5 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Senior Secured Revolving Credit Facility | 225.0 | 11 |
| 2024-04-29 | 2024-Q1 | SG&A as a percentage of revenue | 68.3% | 12 |
| 2024-04-29 | 2024-Q1 | Revenue per active earning coach | $4,623 | 12 |
| 2024-04-29 | 2024-Q1 | Product sales as percentage of revenue (Q1 2024 and 2023) | 98% | 11 |
| 2024-04-29 | 2024-Q1 | Non-GAAP effective tax rate | 28.7% | 12 |
| 2024-04-29 | 2024-Q1 | Non-GAAP adjusted income from operations as a percentage of revenue | 5.3% | 12 |
| 2024-04-29 | 2024-Q1 | Independent Active Earning OPTAVIA Coaches | 37,800 | 12 |
| 2024-04-29 | 2024-Q1 | Income from operations as a percentage of revenue | 4.5% | 12 |
| 2024-04-29 | 2024-Q1 | Gross profit margin | 72.8% | 12 |
| 2024-04-29 | 2024-Q1 | Effective tax rate | 28.2% | 12 |
| 2024-04-29 | 2024-Q1 | Customers impacted to date | 3 million | 11 |
| 2024-04-29 | 2024-Q1 | Cash, cash equivalents, and investments (March 31, 2024) | 156.4 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Cash, cash equivalents, and investments (December 31, 2023) | 150.0 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Cash, Cash Equivalents, and Investment Securities | $156.4 million | 12 |
| 2024-04-29 | 2024-Q1 | Average revenue per active earning OPTAVIA Coach (Q1 2024) | 4,623 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Average revenue per active earning OPTAVIA Coach (Q1 2023) | 5,945 (USD millions) | 11 |
| 2024-04-29 | 2024-Q1 | Active earning OPTAVIA Coaches (March 31, 2024) | 37,800 | 11 |
| 2024-04-29 | 2024-Q1 | Active earning OPTAVIA Coaches (March 31, 2023) | 58,700 | 11 |
| 2024-02-20 | FY2023 | Weight loss market growth rate | approximately 6% | 9 |
| 2024-02-20 | FY2023 | US states obesity 30% or higher | forty-one states | 9 |
| 2024-02-20 | FY2023 | US population wanting weight loss | roughly 75% | 9 |
| 2024-02-20 | FY2023 | US overweight and obese population | more than two-thirds of adult population | 9 |
| 2024-02-20 | FY2023 | US obese population 2022 | more than 30% | 9 |
| 2024-02-20 | FY2023 | Total potential OPTAVIA customers | about 200 million people | 9 |
| 2024-02-20 | FY2023 | scientific journal publications | 28 | 9 |
| 2024-02-20 | FY2023 | Scientific advisory board members | seven | 9 |
| 2024-02-20 | FY2023 | Revenue per active earning coach trend | declining since Q2 2023 | 9 |
| 2024-02-20 | FY2023 | Recognition: 96% lifestyle changes needed | 96% | 9 |
| 2024-02-20 | FY2023 | peer reviewed publications | 33 | 9 |
| 2024-02-20 | FY2023 | overweight obese considering paid meal plans | approximately 70% | 9 |
| 2024-02-20 | FY2023 | OPTAVIA fuelings varieties | more than 45 | 9 |
| 2024-02-20 | FY2023 | medically supported weight loss market 2030 | up to $100 billion | 9 |
| 2024-02-20 | FY2023 | LifeMD shares purchased | 1,224,425 shares | 9 |
| 2024-02-20 | FY2023 | LifeMD investment | $10.0 million (initial) + up to $10.0 million additional | 9 |
| 2024-02-20 | FY2023 | lean muscle mass loss range | 20% to 50% | 9 |
| 2024-02-20 | FY2023 | in-house manufacturing percentage | approximately 25% | 9 |
| 2024-02-20 | FY2023 | customers impacted | more than 3 million | 9 |
| 2024-02-20 | FY2023 | confidence managing alone | only 17% | 9 |
| 2024-02-20 | FY2023 | completed research studies | 28 | 9 |
| 2024-02-20 | FY2023 | coaching study weight loss difference | 15.2 lbs vs 6.7 lbs | 9 |
| 2024-02-20 | FY2023 | Addressable market weight loss | approximately $20 billion | 9 |
| 2024-02-20 | FY2023 | addressable market sports nutrition | $30 billion | 9 |
| 2024-02-20 | FY2023 | Active earning coaches | 41,100 | 9 |
| 2024-02-20 | FY2023 | active coaches decline | from 60,900 (Dec 31, 2022) to 41,100 (Dec 31, 2023) | 9 |
| 2024-02-20 | FY2023 | Working capital (Dec 31, 2023) | $131.7 million | 9 |
| 2024-02-20 | FY2023 | Working capital (Dec 31, 2022) | $81.9 million | 9 |
| 2024-02-20 | FY2023 | Uncommitted Incremental Facility | $100.0 million | 9 |
| 2024-02-20 | FY2023 | Stockholders' equity (Dec 31, 2023) | $201.5 million | 9 |
| 2024-02-20 | FY2023 | Stockholders' equity (Dec 31, 2022) | $155.0 million | 9 |
| 2024-02-20 | FY2023 | Senior secured revolving credit facility amount | $225.0 million | 9 |
| 2024-02-20 | FY2023 | Research and development costs (2023) | $4.6 million | 9 |
| 2024-02-20 | FY2023 | Research and development costs (2022) | $4.5 million | 9 |
| 2024-02-20 | FY2023 | Product sales as % of revenue (2023) | 97.5% | 9 |
| 2024-02-20 | FY2023 | Product sales as % of revenue (2022) | 97.2% | 9 |
| 2024-02-20 | FY2023 | Product sales as % of revenue (2021) | 98.0% | 9 |
| 2024-02-20 | FY2023 | OPTAVIA business unit as % of revenue (2023) | 100% | 9 |
| 2024-02-20 | FY2023 | OPTAVIA business unit as % of revenue (2022) | 100% | 9 |
| 2024-02-20 | FY2023 | OPTAVIA business unit as % of revenue (2021) | 99.9% | 9 |
| 2024-02-20 | FY2023 | Net cash used in investing activities (2023) | $61.0 million | 9 |
| 2024-02-20 | FY2023 | Net cash used in investing activities (2022) | $11.4 million | 9 |
| 2024-02-20 | FY2023 | Net cash used in financing activities (2023) | $79.8 million | 9 |
| 2024-02-20 | FY2023 | Net cash used in financing activities (2022) | $199.6 million | 9 |
| 2024-02-20 | FY2023 | Net cash provided by operating activities (2023) | $147.7 million | 9 |
| 2024-02-20 | FY2023 | Net cash provided by operating activities (2022) | $194.6 million | 9 |
| 2024-02-20 | FY2023 | Letter of credit sublimit | $20.0 million | 9 |
| 2024-02-20 | FY2023 | Cash, cash equivalents and investment securities (Dec 31, 2023) | $150.0 million | 9 |
| 2024-02-20 | FY2023 | Cash, cash equivalents and investment securities (Dec 31, 2022) | $87.7 million | 9 |
| 2024-02-20 | FY2023 | Average revenue per active earning OPTAVIA Coach (Q4 2023) | $4,648 | 9 |
| 2024-02-20 | FY2023 | Average revenue per active earning OPTAVIA Coach (Q4 2022) | $5,538 | 9 |
| 2024-02-20 | FY2023 | Active earning OPTAVIA Coaches (Dec 31, 2023) | 41,100 | 9 |
| 2024-02-20 | FY2023 | Active earning OPTAVIA Coaches (Dec 31, 2022) | 60,900 | 9 |
| 2024-02-20 | 2023-Q4 | Revenue per active earning OPTAVIA Coach | $4,648 | 10 |
| 2024-02-20 | 2023-Q4 | Independent Active Earning OPTAVIA Coaches | 41,100 | 10 |
| 2024-02-20 | 2023-Q4 | Cash, Cash Equivalents, and Investments | $150.0 million | 10 |
| 2023-11-06 | 2023-Q3 | working capital Sep 30 2023 | 114.2 million | 7 |
| 2023-11-06 | 2023-Q3 | working capital Dec 31 2022 | 81.9 million | 7 |
| 2023-11-06 | 2023-Q3 | uncommitted incremental facility | 100.0 million | 7 |
| 2023-11-06 | 2023-Q3 | stockholders equity Sep 30 2023 | 193.0 million | 7 |
| 2023-11-06 | 2023-Q3 | stockholders equity Dec 31 2022 | 155.0 million | 7 |
| 2023-11-06 | 2023-Q3 | senior secured revolving credit facility | 225.0 million | 7 |
| 2023-11-06 | 2023-Q3 | quarterly dividend per share Sep 7 2023 | 1.65 | 7 |
| 2023-11-06 | 2023-Q3 | net income per diluted share Q3 2023 | 2.12 | 7 |
| 2023-11-06 | 2023-Q3 | net income per diluted share Q3 2022 | 3.27 | 7 |
| 2023-11-06 | 2023-Q3 | net income per diluted share 9M 2023 | 8.55 | 7 |
| 2023-11-06 | 2023-Q3 | net income per diluted share 9M 2022 | 10.30 | 7 |
| 2023-11-06 | 2023-Q3 | net cash used in investing activities 9M 2023 | 50.3 million | 7 |
| 2023-11-06 | 2023-Q3 | net cash used in investing activities 9M 2022 | 2.4 million | 7 |
| 2023-11-06 | 2023-Q3 | net cash used in financing activities 9M 2023 | 61.9 million | 7 |
| 2023-11-06 | 2023-Q3 | net cash used in financing activities 9M 2022 | 175.3 million | 7 |
| 2023-11-06 | 2023-Q3 | net cash provided by operating activities 9M 2023 | 137.1 million | 7 |
| 2023-11-06 | 2023-Q3 | net cash provided by operating activities 9M 2022 | 142.8 million | 7 |
| 2023-11-06 | 2023-Q3 | letter of credit sublimit | 20.0 million | 7 |
| 2023-11-06 | 2023-Q3 | cash, cash equivalents and investment securities Sep 30 2023 | 157.8 million | 7 |
| 2023-11-06 | 2023-Q3 | cash, cash equivalents and investment securities Dec 31 2022 | 87.7 million | 7 |
| 2023-11-06 | 2023-Q3 | avg. revenue per active earning OPTAVIA Coach Q3 2023 | 5,008 (USD millions) | 7 |
| 2023-11-06 | 2023-Q3 | avg. revenue per active earning OPTAVIA Coach Q3 2022 | 5,897 (USD millions) | 7 |
| 2023-11-06 | 2023-Q3 | avg. revenue per active earning OPTAVIA Coach 9M 2023 | 5,545 (USD millions) | 7 |
| 2023-11-06 | 2023-Q3 | avg. revenue per active earning OPTAVIA Coach 9M 2022 | 6,367 (USD millions) | 7 |
| 2023-11-06 | 2023-Q3 | active earning OPTAVIA Coaches Q3 2023 | 47,100 | 7 |
| 2023-11-06 | 2023-Q3 | active earning OPTAVIA Coaches Q3 2022 | 66,200 | 7 |
| 2023-11-06 | 2023-Q3 | Revenue per Active Earning Coach | 5,008 (USD millions) | 8 |
| 2023-11-06 | 2023-Q3 | Independent Active Earning OPTAVIA Coaches | 47,100 | 8 |
| 2023-11-06 | 2023-Q3 | Cash, Cash Equivalents, and Investment Securities | 157.8 million | 8 |
| 2023-08-07 | 2023-Q2 | working capital June 2023 | 113.9 million | 5 |
| 2023-08-07 | 2023-Q2 | working capital December 2022 | 81.9 million | 5 |
| 2023-08-07 | 2023-Q2 | stockholders equity June 2023 | 185.6 million | 5 |
| 2023-08-07 | 2023-Q2 | stockholders equity December 2022 | 155.0 million | 5 |
| 2023-08-07 | 2023-Q2 | revolving credit facility | 225.0 million | 5 |
| 2023-08-07 | 2023-Q2 | quarterly dividend declared | 1.65 per share | 5 |
| 2023-08-07 | 2023-Q2 | operating cash flow 6M 2023 | 107.2 million | 5 |
| 2023-08-07 | 2023-Q2 | operating cash flow 6M 2022 | 87.4 million | 5 |
| 2023-08-07 | 2023-Q2 | investing cash flow 6M 2023 | -3.9 million | 5 |
| 2023-08-07 | 2023-Q2 | investing cash flow 6M 2022 | -0.6 million | 5 |
| 2023-08-07 | 2023-Q2 | incremental facility | 100.0 million | 5 |
| 2023-08-07 | 2023-Q2 | financing cash flow 6M 2023 | -43.7 million | 5 |
| 2023-08-07 | 2023-Q2 | financing cash flow 6M 2022 | -130.1 million | 5 |
| 2023-08-07 | 2023-Q2 | diluted EPS Q3 2023 | 2.77 | 5 |
| 2023-08-07 | 2023-Q2 | diluted earnings per share three months 2022 | 3.42 | 5 |
| 2023-08-07 | 2023-Q2 | diluted earnings per share six months 2023 | 6.43 | 5 |
| 2023-08-07 | 2023-Q2 | diluted earnings per share six months 2022 | 7.01 | 5 |
| 2023-08-07 | 2023-Q2 | cash and cash equivalents june 2023 | 147.4 million | 5 |
| 2023-08-07 | 2023-Q2 | cash and cash equivalents december 2022 | 87.7 million | 5 |
| 2023-08-07 | 2023-Q2 | average revenue per active earning coach three months 2023 | 5,578 (USD millions) | 5 |
| 2023-08-07 | 2023-Q2 | average revenue per active earning coach three months 2022 | 6,667 (USD millions) | 5 |
| 2023-08-07 | 2023-Q2 | average revenue per active earning coach six months 2023 | 5,771 (USD millions) | 5 |
| 2023-08-07 | 2023-Q2 | average revenue per active earning coach six months 2022 | 6,603 (USD millions) | 5 |
| 2023-08-07 | 2023-Q2 | active earning coaches june 2023 | 53,100 | 5 |
| 2023-08-07 | 2023-Q2 | active earning coaches june 2022 | 68,000 | 5 |
| 2023-08-07 | 2023-Q2 | Revenue per active earning coach | $5,578 | 6 |
| 2023-08-07 | 2023-Q2 | Independent Active Earning OPTAVIA Coaches | 53,100 | 6 |
| 2023-05-01 | 2023-Q1 | Working capital | $98.6 million | 3 |
| 2023-05-01 | 2023-Q1 | Uncommitted incremental facility capacity | $100.0 million | 3 |
| 2023-05-01 | 2023-Q1 | Stockholders' equity | $170.9 million | 3 |
| 2023-05-01 | 2023-Q1 | SG&A as percentage of revenue | 55.3% | 3 |
| 2023-05-01 | 2023-Q1 | Net cash provided by operating activities | $64.1 million | 3 |
| 2023-05-01 | 2023-Q1 | Lives impacted to date | more than 3 million | 3 |
| 2023-05-01 | 2023-Q1 | Income from operations percentage | 15.3% | 3 |
| 2023-05-01 | 2023-Q1 | Effective tax rate | 25.1% | 3 |
| 2023-05-01 | 2023-Q1 | Diluted earnings per share | $3.67 | 3 |
| 2023-05-01 | 2023-Q1 | Cash and cash equivalents | $123.7 million | 3 |
| 2023-05-01 | 2023-Q1 | Average revenue per active earning OPTAVIA Coach (Q1 2023) | $5,945 | 3 |
| 2023-05-01 | 2023-Q1 | Average revenue per active earning OPTAVIA Coach (Q1 2022) | $6,536 | 3 |
| 2023-05-01 | 2023-Q1 | Available credit facility | $225.0 million | 3 |
| 2023-05-01 | 2023-Q1 | Active earning OPTAVIA Coaches | 58,700 | 3 |
Advertisement
Guidance Tracking (latest per metric/period · 16/32)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
Actuals: revenue in $m · EPS in $ per share
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-08-03 | Loss per share | 0.25–1.75 | – | pending | initiated | 30 |
| FY2026 | 2026-02-17 | Revenue | 270–300 | – | pending | initiated | 30 |
| 2026-Q3 | 2026-08-03 | Revenue | 60–80 | – | pending | initiated | 30 |
| 2026-Q3 | 2026-08-03 | Loss per share | 0.15–0.65 | – | pending | initiated | 30 |
| 2026-Q2 | 2026-05-04 | Revenue | 60–80 | 76.4 | in line | initiated | 28 |
| 2026-Q2 | 2026-05-04 | Loss per share | 0.5–1 | – | – | initiated | 28 |
| 2026-Q1 | 2026-02-17 | Revenue | 65–80 | 76 | in line | initiated | 26 |
| 2026-Q1 | 2026-02-17 | Loss per share | 0.15–0.7 | – | – | initiated | 26 |
| 2025-Q4 | 2025-11-03 | Revenue | 65–80 | 75.1 | in line | initiated | 24 |
| 2025-Q4 | 2025-11-03 | Diluted loss per share | 0.7–1.25 | – | – | initiated | 24 |
| 2025-Q3 | 2025-08-04 | Revenue | 70–90 | 89.4 | in line | initiated | 22 |
| 2025-Q3 | 2025-08-04 | EPS (GAAP) | -0.6–0 | -0.21 | in line | initiated | 22 |
| 2025-Q2 | 2025-04-28 | Revenue | 85–105 | 105.6 | beat | initiated | 20 |
| 2025-Q2 | 2025-04-28 | Loss per share | 0–0.55 | – | – | initiated | 20 |
| 2025-Q1 | 2025-02-18 | Revenue | 100–120 | 115.7 | in line | initiated | 18 |
| 2025-Q1 | 2025-02-18 | EPS (GAAP) | 0–0.5 | -0.07 | miss | initiated | 18 |
| 2024-Q4 | 2024-11-04 | Revenue | 100–120 | 119 | in line | initiated | 16 |
| 2024-Q4 | 2024-11-04 | Diluted loss per share | 0.1–0.65 | – | – | initiated | 16 |
| 2024-Q3 | 2024-08-05 | Revenue | 125–145 | 140.2 | in line | initiated | 14 |
| 2024-Q3 | 2024-08-05 | Diluted loss per share | 0.05–0.7 | – | – | initiated | 14 |
| 2024-Q2 | 2024-04-29 | Revenue | 150–170 | 168.6 | in line | initiated | 12 |
| 2024-Q2 | 2024-04-29 | EPS (GAAP) | 0.05–0.4 | -0.75 | miss | initiated | 12 |
| 2024-Q1 | 2024-02-20 | Revenue | 155–175 | 174.7 | in line | initiated | 10 |
| 2024-Q1 | 2024-02-20 | EPS (GAAP) | 0.25–0.95 | 0.76 | in line | initiated | 10 |
| FY2023 | 2023-11-06 | EPS (GAAP) | 8.65–9.55 | 9.1 | in line | confirmed | 8 |
| FY2023 | 2023-11-06 | Full-year 2023 revenue | 1,050–1,070 | – | – | confirmed | 8 |
| 2023-Q3 | 2023-08-07 | Revenue | 220–240 | 235.9 | in line | initiated | 6 |
| 2023-Q3 | 2023-08-07 | EPS (GAAP) | 0.71–1.32 | 2.12 | beat | initiated | 6 |
| 2023-Q2 | 2023-05-01 | Revenue | 250–270 | 296.2 | beat | initiated | 4 |
| 2023-Q2 | 2023-05-01 | EPS (GAAP) | 1.32–1.44 | 2.77 | beat | initiated | 4 |
| 2023-Q1 | 2023-02-21 | Revenue | 300–320 | 349 | beat | initiated | 2 |
| 2023-Q1 | 2023-02-21 | EPS (GAAP) | 1.75–2.4 | 3.67 | beat | initiated | 2 |
Advertisement
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2026
In H1 FY2026, Medifast reported combined revenue of $152.4 million, a 31.1% year-over-year decline from $221.3 million in H1 2025, driven by a contraction in the active earning coach network from approximately 25,400 in Q1 2025 to 11,700 by Q2 2026 29. Quarterly revenue fell 34.3% in Q1 to $76.0 million and 27.6% in Q2 to $76.4 million, with gross margins compressing to 68.1% and 69.9% respectively due to loss of fixed-cost leverage 27 29. The company recorded an H1 net loss of $5.2 million compared to net income of $1.7 million in H1 2025, while maintaining a strong balance sheet with approximately $169.8 million in cash and investment securities and no debt 29 30. Medifast initiated a strategic transformation in response to headwinds including competition from GLP-1 weight loss medications, launching the Metabolic Synchronization science framework in October 2025, the Trilivy brand and Medifast Metabolic Health Institute in July 2026, and the Catalyst cost-savings program focused on facility rationalization and AI-related efficiencies 27 29 30. Full-year 2026 revenue guidance of $270 million to $300 million was issued, with a return to profitability targeted for Q4 2026 30.
FY2025
Medifast's FY2025 revenue fell 36.0% to $385.8 million from $602.5 million in 2024, driven by a 40.6% decline in active earning OPTAVIA coaches to 16,100, reflecting sustained challenges in customer acquisition and broader market adoption of GLP-1 medications (25). Gross profit margin compressed 250 basis points to 71.3% due to loss of leverage on fixed costs, and the company recorded a full-year net loss of $18.7 million compared to net income of $2.1 million in 2024 (25). In response to the GLP-1 competitive environment, the company introduced the GLP-1 Nutrition Support Plan with the OPTAVIA ASCEND product line, established a collaboration with LifeMD to provide coach clients access to GLP-1 medications, and later announced a strategic reorientation under the Metabolic Synchronization framework targeting holistic metabolic health (19, 25). The Amended Credit Agreement with Citibank was terminated in October 2024 with no outstanding borrowings, and the company ended FY2025 with $167.3 million in cash, cash equivalents, and investment securities and no interest-bearing debt (25, 26). In Q4 2025, the company reinstated annual guidance for 2026 after a two-year absence and reported coach productivity turned positive year-over-year for the first time since 2022 (26).
FY2024
Medifast's full-year 2024 revenue declined 43.8% to $602.5 million from $1.1 billion in 2023, primarily driven by a 34.1% decrease in active earning OPTAVIA coaches from 41,100 to 27,100 and lower coach productivity 17. Gross profit margin improved 140 basis points to 73.8%, supported by inventory management efficiencies and savings from the Fuel for the Future program 17. Net income fell 97.9% to $2.1 million from $99.4 million in 2023 as revenue declines exceeded cost efficiencies 17. To address the expanding medically supported weight loss market, the company established a collaboration with LifeMD in December 2023 for GLP-1 medication access, launched a company-led marketing campaign incurring approximately $22.9 million in advertising expenses in 2024, and introduced the GLP-1 Nutrition Support Plan, Optimization Plan, and OPTAVIA ASCEND product line in December 2024 17. The company ended 2024 with $162.3 million in cash and investment securities and no interest-bearing debt 18.
FY2023
Medifast's full-year 2023 revenue fell 32.9% to $1.072 billion from $1.599 billion in 2022, driven by a 32.5% decline in active earning OPTAVIA Coaches (from 60,900 to 41,100) and a 16.1% decrease in average revenue per active earning Coach 9. Despite the volume contraction, full-year gross margin improved 110 basis points to 72.4% as cost savings from the Fuel for the Future program more than offset fixed-cost deleverage 9. Net income decreased to $99.4 million ($9.10 per diluted share) from $143.6 million ($12.73) in 2022, while free cash flow reached $141.2 million and cash plus investment securities grew to $150.0 million from $87.7 million at year-end 2022 9. Strategically, the company exited Asia Pacific operations in Hong Kong and Singapore, launched the OPTAVIA ACTIVE sports nutrition line in September 2023, and in December 2023 announced a collaboration with LifeMD to enter the medically supported weight loss market, including access to GLP-1 medications 9. The quarterly cash dividend was discontinued effective December 7, 2023 to redirect capital toward technology investments and future growth initiatives 9.
Advertisement
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
46 documents · 2016 – 2026 · SEC EDGAR (USA)
| # | Document type | Published | Link |
|---|---|---|---|
| #1 | 10-K | 2023-02-21 | Open |
| #2 | 8-K-EX99.1 | 2023-02-21 | Open |
| #3 | 10-Q | 2023-05-01 | Open |
| #4 | 8-K-EX99.1 | 2023-05-01 | Open |
| #5 | 10-Q | 2023-08-07 | Open |
| #6 | 8-K-EX99.1 | 2023-08-07 | Open |
| #7 | 10-Q | 2023-11-06 | Open |
| #8 | 8-K-EX99.1 | 2023-11-06 | Open |
| #9 | 10-K | 2024-02-20 | Open |
| #10 / #110 | 8-K-EX99.1 | 2024-02-20 | Open |
| #11 | 10-Q | 2024-04-29 | Open |
| #12 | 8-K-EX99.1 | 2024-04-29 | Open |
| #13 | 10-Q | 2024-08-05 | Open |
| #14 | 8-K-EX99.1 | 2024-08-05 | Open |
| #15 | 10-Q | 2024-11-04 | Open |
| #16 | 8-K-EX99.1 | 2024-11-04 | Open |
| #17 | 10-K | 2025-02-18 | Open |
| #18 / #118 | 8-K-EX99.1 | 2025-02-18 | Open |
| #19 | 10-Q | 2025-04-28 | Open |
| #20 | 8-K-EX99.1 | 2025-04-28 | Open |
| #21 | 10-Q | 2025-08-04 | Open |
| #22 | 8-K-EX99.1 | 2025-08-04 | Open |
| #23 | 10-Q | 2025-11-03 | Open |
| #24 | 8-K-EX99.1 | 2025-11-03 | Open |
| #25 | 10-K | 2026-02-17 | Open |
| #26 / #126 | 8-K-EX99.1 | 2026-02-17 | Open |
| #27 | 10-Q | 2026-05-04 | Open |
| #28 | 8-K-EX99.1 | 2026-05-04 | Open |
| #29 | 10-Q | 2026-08-03 | Open |
| #30 | 8-K-EX99.1 | 2026-08-03 | Open |
Older sources (+16)
| # | Document type | Published | Link |
|---|---|---|---|
| #202 | 10-K | 2016-05-10 | Open |
| #201 | 10-Q | 2016-08-09 | Open |
| #204 | 10-K | 2017-03-16 | Open |
| #203 | 10-Q | 2017-08-09 | Open |
| #205 | 10-Q | 2018-03-16 | Open |
| #207 | 10-K | 2018-03-16 | Open |
| #206 | 10-Q | 2018-08-06 | Open |
| #209 | 10-K | 2019-03-01 | Open |
| #208 | 10-Q | 2019-08-02 | Open |
| #213 | 10-K | 2020-03-02 | Open |
| #210 | 10-Q | 2020-05-06 | Open |
| #211 | 10-Q | 2020-08-06 | Open |
| #212 | 10-Q | 2020-11-03 | Open |
| #214 | 10-Q | 2021-05-04 | Open |
| #215 | 10-Q | 2021-08-04 | Open |
| #216 | 10-Q | 2021-11-04 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Loss per share. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Does Medifast Inc. pay a dividend?
The filings report on the dividend; most recent entry: dividend per share 1.65 (2023-Q3) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Medifast Inc.?
The sources chapter links all 49 original filings used (SEC filings) with type, publication date and a direct link; every figure in the report carries a source number.
More reports#
Recently updated
Advertisement